Ophiomics and Biocartis to Collaborate on Liver Cancer Test

Ophiomics (PT) and Biocartis (BE) announce today that they have entered into a collaboration regarding HepatoPredict™, a prognostic test for liver cancer. HepatoPredict™ will be launched as a CE-marked IVD manual kit in Q1 2022. The partnership will initially focus on Biocartis’ commercialization of the manual kit in Europe. In a next stage, depending on successful commercial uptake of the manual kit, Ophiomics and Biocartis aim to initiate the development of a fully automated version of the test on Biocartis’ decentralized Idylla™ platform.

The development, validation and industrialisation of HepatoPredict™ by Ophiomics was supported by an EIC Accelerator Grant and investment from the EIC Fund.

A link to the press release in English can be found here

O comunicado de imprensa em Português encontra-se abaixo: